SCHEMBL1502536

SCHEMBL1502536

CC(=O)Nc1ccc(S(=O)(=O)Nc2cc(C)on2)cc1

nearest known ligand 0.75

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.75
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
HSP90AA1 P07900 1/20 0.73
HSP90AB1 P08238 1/20 0.73
PPIA P62937 3/20 0.70
AMY1A P0DUB6 1/20 0.69
MAPT P10636 1/20 0.66
GFER P55789 1/20 0.66
CHIA Q9BZP6 1/20 0.65
THRB P10828 1/20 0.65
ALOX12 P18054 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6670019 0.96 ALDH1A1 (0.70) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL2871844 0.87 ALDH1A1 (0.69) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL21795038 0.87 KMT2A (0.80) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL2871247 0.85 CHIA (0.80) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL5565268 0.83 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL12010930 0.83 HSP90AA1 (0.83) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
Sulfamethoxazole SCHEMBL20456610 0.82 ALDH1A1 (0.89) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL31469213 0.81 ALDH1A1 (0.73) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL5339369 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1
SCHEMBL12879697 0.81 ALDH1A1 (0.77) ALDH1A1MEN1KMT2AHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110441447-B Deuterated sulfamethoxazole-d4Method of synthesis of 雅安职业技术学院 2022-04-08 CN claimed
CN-107991409-B Method for simultaneously measuring 12 sulfonamides in blood plasma by adopting high-efficiency synthetic phase chromatography 中国医学科学院肿瘤医院 2020-04-24 CN claimed
CN-110003128-A A kind of sulfamethoxazole and its synthetic method of stable isotope labeling 上海安谱实验科技股份有限公司 2019-07-12 CN claimed
US-20160325012-A1 GEL-FORMING AGENT COMPRISING SULFA AGENT AND CHITOSAN AGENT AND HAVING POWDERED DOSAGE FORM GREENEVER (JP) 2016-11-10 US claimed
EP-3087990-A1 GEL-FORMING AGENT CONTAINING SULFONAMIDE AND CHITOSAN AND HAVING A POWDERED DOSAGE FORM Greenever (JP) 2016-11-02 EP claimed
CN-120064476-A Solid phase extraction-ultra-high performance liquid chromatography-tandem mass spectrometry rapid determination method for various antibiotics in human urine 复旦大学 2025-05-30 CN disclosed
WO-2025088151-A1 ENHANCED METABOLIC MEDIUM FOR CULTURING PLURIPOTENT STEM CELLS UNIVERSITY OF COPENHAGEN (DK) 2025-05-01 WO disclosed
CN-119889726-A Semen quality prediction method and system based on random forest 深圳市疾病预防控制中心(深圳市卫生监督局、深圳市卫生检验中心、深圳市预防医学研究所) 2025-04-25 CN disclosed
WO-2025036962-A1 METHOD AND SYSTEM FOR WASTEWATER TREATMENT AND NUTRIENT RECOVERY EAWAG EIDG. ANSTALT FÜR WASSERVERSORGUNG, ABWASSERREINIGUNG UND GEWÄSSERSCHUTZ (CH) 2025-02-20 WO disclosed
EP-4509470-A1 METHOD AND SYSTEM FOR WASTEWATER TREATMENT AND NUTRIENT RECOVERY EAWAG Eidg. Anstalt für Wasserversorgung Abwasserreinigung und Gewässerschutz (CH) 2025-02-19 EP disclosed
WO-2025021378-A1 METHOD TO DETECT CONTAMINATION WITH ANTIBIOTIC METABOLITES AND METHOD TO REDUCE OR AVOID DEVELOPMENT OF ANTIBIOTIC RESISTANCE TECHNOLOGICAL UNIVERSITY DUBLIN (IE) 2025-01-30 WO disclosed
US-11845681-B2 Process and plant for treating wastewater containing micropollutants of pharmaceutical origin COCKERILL MAINTENANCE & INGENIERIE S.A. (BE) 2023-12-19 US disclosed
US-20030092754-A1 External preparation for skin diseases containing nitroimidazole SHOEI CO., LTD. (JP) 2003-05-15 US disclosed
US-6416546-B1 Medical device and production method thereof UNITIKA LTD. (JP) 2002-07-09 US disclosed
EP-1206937-A1 NITROIMIDAZOLE EXTERNAL PREPARATIONS FOR DERMATOSIS SHOEI CO., LTD. (JP) 2002-05-22 EP disclosed
CN-1316897-A Dosage form comprising liquid formulation ALZA CORP (US) 2001-10-10 CN disclosed
CN-1211928-A Method for increasing solubility of substantially water-insoluble compounds UNION CARBIDE CHEM PLASTIC (US) 1999-03-24 CN disclosed
EP-0882461-A2 Medical device and production method thereof UNITIKA LTD. (JP) 1998-12-09 EP disclosed
CN-1191476-A Oral delivery of discrete units ALZA CORP (US) 1998-08-26 CN disclosed
EP-0055609-A1 Composition for coelomic administration, its preparation, and ingredients for use therein SHIONOGI & CO., LTD. (JP) 1982-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092754-A1 External preparation for skin diseases containing nitroimidazole IL4I1, NSD1, CUTA ALDH1A1 776/4885MEN1 3791/4885KMT2A 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.